SIDEWINDER THERAPEUTICS Trademark

Trademark Overview


On Monday, December 11, 2023, a trademark application was filed for SIDEWINDER THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the SIDEWINDER THERAPEUTICS trademark a serial number of 98307987. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, February 11, 2025. This trademark is owned by Sidewinder Therapeutics, Inc.. The SIDEWINDER THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for the treatment and prevention of diseases in humans, namely, cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, acute respiratory disease, and rare autoimmune, viral and infectious diseases; pharmaceutical preparations, namely, a drug formulation for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, oncology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation for use in pediatrics, geriatrics, emergency psychiatry, family psychiatry, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases; pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with the muscular system...
sidewinder therapeutics

General Information


Serial Number98307987
Word MarkSIDEWINDER THERAPEUTICS
Filing DateMonday, December 11, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, February 11, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2025

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for the treatment and prevention of diseases in humans, namely, cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, acute respiratory disease, and rare autoimmune, viral and infectious diseases; pharmaceutical preparations, namely, a drug formulation for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, oncology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation for use in pediatrics, geriatrics, emergency psychiatry, family psychiatry, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases; pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system; pharmaceutical preparations for the treatment or prevention of muscle loss, metabolic conditions and diseases, gastrointestinal conditions and diseases, neurological conditions and diseases, cancer, osteoporosis, inflammatory conditions and diseases, genetic conditions and diseases, muscle diseases and disorders, hepatic conditions and diseases, fibrosis, malnutrition, atrophic diseases and conditions, epilepsy, sarcopenia, myopathies, neuropathies, neurodegenerative diseases, traumatic brain injury, concussions, movement disorders, dystrophies, anemias, and orphan diseases; pharmaceutical and biological preparations, namely, precision therapeutics for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system; pharmaceutical and biological preparations, namely, large molecule precision therapeutics for the treatment or prevention of diseases, disorders and conditions associated with the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, and the integumentary system
NOT AVAILABLE"THERAPEUTICS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSidewinder Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Party NameSidewinder Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Monday, December 11, 2023NEW APPLICATION ENTERED
Wednesday, July 10, 2024ASSIGNED TO EXAMINER
Monday, March 11, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 5, 2024NON-FINAL ACTION WRITTEN
Monday, August 5, 2024NON-FINAL ACTION E-MAILED
Wednesday, August 7, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, January 17, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 17, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 17, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 21, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 5, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 11, 2025PUBLISHED FOR OPPOSITION
Tuesday, February 11, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, August 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 7, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED